TRIM21

Across TCGA pan-cancer cohorts, TRIM21 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TRIM21’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TRIM21 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TRIM21 is over-expressed in tumor, although a few such as LSCC and COAD show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where TRIM21 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRIM21 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	+0.637	<.001	12	view →
HNSC	Male	IV	+0.571	<.001	8	view →
LSCC	Male	III,IV	−0.376	<.001	8	view →
PDAC	Female	All	+0.491	<.001	6	view →
COAD	Male	III,IV	−0.182	.019	4	view →
LUAD	Male	All	−0.147	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TRIM21–CCRCC

Open the CCRCC breakdown →